LEGN 240517 40.00C (LEGN240517C40000) Stock Options, News & Quotes

US OptionsDetailed Quotes

LEGN240517C40000

Watchlist

4.10
+0.70+20.59%

15min DelayClose May 14 15:59 ET

4.10High3.00Low

Intraday

News

Legend Biotech Price Target Raised to $86.00/Share From $85.00 by RBC Capital
Legend Biotech Price Target Raised to $86.00/Share From $85.00 by RBC Capital
Dow JonesMay 14 11:41 ET
Analysts Offer Insights on Healthcare Companies: Legend Biotech (LEGN), Green Thumb Industries (OtherGTBIF) and OmniAb (OABI)
TipRanksMay 14 08:10 ET
Legend Biotech's Loss Narrows in Q1 as Revenue Surges
Genscript Biotech's (HKG:1548) Nasdaq-listed subsidiary Legend Biotech reported a loss of $59.8 million, or $0.16 per share, in the first quarter, down from $112.1 million, or $0.34 per share, a year
MT NewswiresMay 14 07:44 ET
Scotiabank Sticks to Their Buy Rating for Legend Biotech (LEGN)
TipRanksMay 14 07:37 ET
Buy Rating for Legend Biotech Anchored by Carvykti's Growth and Market Penetration Potential
TipRanksMay 14 07:25 ET
Legend Biotech Is Maintained at Buy by HC Wainwright & Co.
Legend Biotech Is Maintained at Buy by HC Wainwright & Co.
Dow JonesMay 14 07:07 ET

Comments

Meltyy

Apr 9 23:48

FDA PDUFA Update…

🗓️ Last week’s PDUFAs:
$Supernus Pharmaceuticals(SUPN.US)$ : CRL 4/8/24 🙁
⇒ SPN-830
⇒ OFF episodes in PD
⇒ NDA
⇒ PDUFA: 4/5/24
$Legend Biotech(LEGN.US)$ & $Johnson & Johnson(JNJ.US)$ : Approved 🎉
⇒ CARVYKTI (cilta-cel)
⇒ Multiple myeloma
⇒ sBLA
⇒ PDUFA: 4/5/24
$AstraZeneca(AZN.US)$ : Approved 🎉
⇒ Enhertu
⇒ HER2+ solid tumors
⇒ sBLA
⇒ PDUFA: Q2 2024
$2seventy bio(TSVT.US)$ & $Bristol-Myers Squibb(BMY.US)$ : Approved 🎉
⇒ Abecma
⇒ Multiple myeloma
⇒ sBLA
⇒ Delayed PDUFA
$Vanda Pharmaceuticals(VNDA.US)$...

Lilo und Stitch

Apr 4 22:36

$Legend Biotech(LEGN.US)$
waiting patiently for fda 😌🙏✨

Meltyy

Apr 2 10:41

FDA PDUFA Update…

🗓️ Last week’s PDUFAs:
$Akebia Therapeutics(AKBA.US)$ : Approved 🎉
⇒ Vafseo (Vadadustat)
⇒ Anemia due to CKD
⇒ NDA
⇒ PDUFA: 3/27/24
$Merck & Co(MRK.US)$ : Approved 🎉
⇒ WINREVAIR (sotatercept)
⇒ Pulmonary arterial hypertension
⇒ BLA
⇒ PDUFA: 3/26/24
$AstraZeneca(AZN.US)$ : Approved 🎉
⇒ Ultomiris (ravulizumab)
⇒ NMOSD
⇒ sBLA
$Regeneron Pharmaceuticals(REGN.US)$ : CRL 🙁
⇒ Odronextamab
⇒ r/r FL and r/r DLBCL
⇒ BLA
⇒ PDUFA: 3/31/24
📌 This week’s PDUFAs: 🚨
$AstraZeneca(AZN.US)$ : 🤔
⇒...

The FDA PDUFA Calendar is a chronological calendar of PDUFA target dates as well as Advisory meetings (ADCOMM). PDUFA target dates are dates by which the FDA aims to deliver their decision regarding an NDA or BLA filing. These decisions can however come before the PDUFA target date.
$Vanda Pharmaceuticals(VNDA.US)$ $Legend Biotech(LEGN.US)$ $Supernus Pharmaceuticals(SUPN.US)$ $ImmunityBio(IBRX.US)$ $Aquestive Therapeutics(AQST.US)$ $X4 Pharmaceuticals(XFOR.US)$ $Liquidia(LQDA.US)$ $Neurocrine Biosciences(NBIX.US)$ $Moderna(MRNA.US)$ $Day One Biopharmaceuticals(DAWN.US)$
...

Meltyy

Mar 14 18:23

AdCom for CARVYKTI on 3/15

$Legend Biotech(LEGN.US)$ $Johnson & Johnson(JNJ.US)$
⇨ FDA’s briefing docs released today! 🔔
⚠️ Early deaths in cilta-cel arm raise FDA concern despite PFS benefit... 🤔
$LEGN trending up ~6% after doc release 📈
ℹ️ CARVYKTI (ciltacabtagene autoleucel)
⇒ multiple myeloma
⇒ CARTITUDE-4 study
⇒ sBLA
⇒ PDUFA: 4/5/24
❓AdCom Discussion & Question:
Discussion Topic:
⇒ Discuss whether the results of CARTITUDE-4 provided in the supplemental application are sufficient to support a positive...